An open-label pilot study of the efficacy and safety of anakinra in patients with psoriatic arthritis refractory to or intolerant of methotrexate (MTX)

2010 ◽  
Vol 29 (10) ◽  
pp. 1169-1173 ◽  
Author(s):  
Norma Jung ◽  
Matthias Hellmann ◽  
Reimund Hoheisel ◽  
Clara Lehmann ◽  
Ingo Haase ◽  
...  
Keyword(s):  
Psoriatic Arthritis ◽  
Pilot Study ◽  
Efficacy And Safety ◽  
Open Label

scholarly journals Efficacy and Safety of Reslizumab in Patients with Severe Asthma with Inadequate Response to Omalizumab: A Multicenter, Open-Label Pilot Study

2019 ◽  
Vol 7 (7) ◽  
pp. 2277-2283.e2 ◽  
Author(s):  
Luis A. Pérez de Llano ◽  
Borja G. Cosío ◽  
Christian Domingo ◽  
Isabel Urrutia ◽  
Irina Bobolea ◽  
...  
Keyword(s):  
Pilot Study ◽  
Severe Asthma ◽  
Inadequate Response ◽  
Efficacy And Safety ◽  
Open Label

scholarly journals Efficacy and safety of curcumin in primary sclerosing cholangitis: an open label pilot study

2019 ◽  
Vol 54 (5) ◽  
pp. 633-639 ◽  
Author(s):  
John E. Eaton ◽  
Kevin M. Nelson ◽  
Andrea A. Gossard ◽  
Elizabeth J. Carey ◽  
James H Tabibian ◽  
...  
Keyword(s):  
Pilot Study ◽  
Primary Sclerosing Cholangitis ◽  
Sclerosing Cholangitis ◽  
Efficacy And Safety ◽  
Open Label

Pilot Study to Evaluate the Efficacy and Safety of Oral Tacrolimus in Adult Patients With Refractory Severe Plaque Psoriasis

2015 ◽  
Vol 20 (3) ◽  
pp. 228-232 ◽  
Author(s):  
Ankit Mittal ◽  
Sunil Dogra ◽  
Tarun Narang ◽  
Aman Sharma
Keyword(s):  
Pilot Study ◽  
Plaque Psoriasis ◽  
Severity Index ◽  
Term Treatment ◽  
Adult Patients ◽  
Efficacy And Safety ◽  
Open Label ◽  
Short Term Treatment ◽  
Psoriasis Area Severity Index ◽  
Severe Plaque Psoriasis

Background: Tacrolimus, a congener of cyclosporine, has replaced cyclosporine as a first-line treatment for most transplant patients due to its superior efficacy and safety. Tacrolimus has not been extensively studied for the treatment of psoriasis. Objectives: To study the efficacy and safety of oral tacrolimus in adult patients with severe refractory plaque psoriasis. Methods: This was an open-label pilot study. Patients with severe plaque type psoriasis who were unresponsive to at least 1 systemic treatment were treated with oral tacrolimus. Results: Thirty patients were treated. After 12 weeks, improvement in mean Psoriasis Area Severity Index (PASI) score was 80.37% ( P < .001), PASI 75 was observed in 19 of 26 (73.1%) patients, and PASI 90 was observed in 11 of 26 (42.3%) patients. No severe side effects were noted. Conclusion: Oral tacrolimus is an effective and safe option for the short-term treatment of severe plaque psoriasis.

scholarly journals Efficacy and safety of atorvastatin in South Asian patients with dyslipidemia: an open label noncomparative pilot study

2005 ◽  
Vol 1 (4) ◽  
pp. 351-356 ◽  
Author(s):  
Jeetesh V Patel ◽  
Sandeep Gupta ◽  
Frank Lie ◽  
Elizabeth A Hughes
Keyword(s):  
Pilot Study ◽  
South Asian ◽  
Efficacy And Safety ◽  
Open Label ◽  
Asian Patients
Sign in / Sign up

Export Citation Format

Share Document